NHS Framework Agreement for the supply of Icatibant and C1 Esterase products for the treatment of Hereditary Angioedema
NHS Framework Agreement for the supply of Icatibant and C1-Esterase products for the treatment of Hereditary Angioedema. The framework will commence on 1st July 2018 for a period of 12 months until 30th June 2019, with options to extend up to a further 36 months.
Buyer
NHS England
Value
£72,000,000
Published
16 Jul 2018
Closes
29 Mar 2018
Procurement details
Source
Contracts Finder
Region
United Kingdom
Procurement method
Open
Category
Goods
Contract starts
30 Jun 2018
Contract ends
30 Jun 2019
CPV classifications
33600000
Pharmaceutical products
Lots
Lot default NHS Framework Agreement for the supply of Icatibant and C1 Esterase products for the treatment of Hereditary Angioedema
£72,000,000
NHS Framework Agreement for the supply of Icatibant and C1-Esterase products for the treatment of Hereditary Angioedema. The framework will commence on 1st July 2018 for a period of 12 months until 30th June 2019, with options to extend up to a further 36 months.
Delivery: British Oversea Territories, Channel Islands, Europe, Isle of Man, Northern Ireland · United Kingdom, Rest of the World
Documents
Unlock document linkOpportunity notice on Contracts Finder
27 Feb 2018
Opportunity notice on Contracts Finder
Tender notice · Web page
n/a
Not provided
n/a
Tender notice · Word document
n/a
Not provided
n/a
Tender notice · Word document
n/a
Not provided
n/a
Tender notice · Word document
n/a
Not provided
n/a
Tender notice · Word document
n/a
Not provided
n/a
Tender notice · Word document
n/a
Not provided
n/a
Tender notice · Excel spreadsheet
n/a
Not provided
n/a
Tender notice · Excel spreadsheet
n/a
Not provided
n/a
Tender notice · Excel spreadsheet
n/a
Not provided
n/a
Tender notice · File
n/a
Not provided
n/a
Tender notice · Word document
n/a
Not provided
n/a
Tender notice · Word document
Contains public sector information licensed under the Open Government Licence v3.0.